Estudio observacional de eficacia y seguridad del cambio de insulina NPH a glargina en atención primaria. Estudio LAURA

espanolObjetivo Evaluar la eficacia y la seguridad del cambio de insulina NPH a insulina glargina en pacientes con diabetes mellitus tipo2 (DM2) atendidos en atencion primaria. Material y metodos Estudio observacional retrospectivo. Cuarenta y seis medicos de atencion primaria registraron la informacion clinica de pacientes tratados previamente con insulina NPH que cambiaron a glargina o siguieron con NPH a los 3-9meses despues de la visita de inclusion (diseno de inclusion glargina2:NPH1). Resultados Se analizaron 122pacientes del grupo glargina y 57 del grupo NPH (edad 67,0 [±9,8] anos, 51,4% varones). Entre la visita inicial y la final se observaron reducciones de HbA1c de 1,07 (±0,93)% vs 0,28 (±0,67)% (p Conclusiones Los pacientes con DM2 atendidos en atencion primaria que cambian de insulina NPH a glargina presentan una mejora significativa del control glucemico y una menor frecuencia de hipoglucemias totales y nocturnas. EnglishObjective To assess the efficacy and safety of insulin Glargine in the Primary Care setting for patients with type2 diabetes mellitus (DM2) previously treated with NPH insulin. Material and methods This was an observational retrospective study, with 46participating Primary Care physicians, who recorded the clinical information of patients treated with NPH insulin and who switched to insulin Glargine or continued on NPH for 3-9months (inclusion design 2Glargine:1NPH). Results A total of 122patients in the Glargine group, and 57patients in the NPH insulin group were evaluated; the patients had a mean age of 67.0 (9.8) years, and 51.4% were males. A difference in HbA1c reduction was seen when comparing the Glargine and NPH groups: 1.07 (0.93)% vs. 0.28 (0.67)%, respectively (P Conclusion Patients with DM2 who are treated with NPH insulin in Primary Care and switch to Glargine show better glycemic control and experience fewer total and nocturnal hypoglycemic episodes.